Innovent Seeks Chinese Regulatory Approval for Proposed Biosimilar Bevacizumab
January 30th 2019
By Samantha DiGrande
ArticleInnovent Biologics, a China-based biopharmaceutical company, recently submitted a New Drug Application for its proposed bevacizumab biosimilar, IBI-305, referencing Avastin, to the Chinese regulatory agency, the National Medical Products Administration.